Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Safety and Feasibility of UMC119-01 Cell Therapy in Infants at High Risk for Bronchopulmonary Dysplasia

NCT03631420 is registered in ClinicalTrials.gov with Meridigen Biotech Co., Ltd. as lead sponsor.

NCT NCT03631420
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03631420 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Safety and Feasibility of UMC119-01 Cell Therapy in Infants at High Risk for Bronchopulmonary Dysplasia
Lead sponsor
Meridigen Biotech Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
October 26, 2018
Completion date
July 31, 2027
Enrollment
9 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bronchopulmonary dysplasia